Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC
No Thumbnail Available
Identifiers
Date
2019-10-01
Authors
Felip, E.
Brunsvig, P.
Helland, A.
Vinolas, N.
Aix, S.
Carcereny, E.
Domine Gomez, M.
Trigo Perez, J. M.
Arriola, E.
Garcia Campelo, R.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
bemcentinib, AXL, Pembrolizumab